WO2010061074A1 - Derives indoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent - Google Patents
Derives indoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent Download PDFInfo
- Publication number
- WO2010061074A1 WO2010061074A1 PCT/FR2009/001338 FR2009001338W WO2010061074A1 WO 2010061074 A1 WO2010061074 A1 WO 2010061074A1 FR 2009001338 W FR2009001338 W FR 2009001338W WO 2010061074 A1 WO2010061074 A1 WO 2010061074A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- pharmaceutically acceptable
- acceptable base
- addition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention relates to novel indole derivatives, process for their preparation and pharmaceutical compositions containing them.
- the compounds of the present invention are novel and have very interesting pharmacological characteristics concerning melatoninergic receptors.
- melatonin N-acetyl-5-methoxytryptamine
- melatonin analogues which are metabolically more stable and have an agonist or antagonist character, which can be expected to have a therapeutic effect greater than that of the hormone itself.
- the melatoninergic system ligands possess interesting pharmacological properties - on the central nervous system, including anxiolytics and antipsychotics (Neuropharmacology of Pineal Secretions, 1990, 8 (3-4), pp. 264-272), analgesics (Pharmacopsychiat., 1987, 20, pp. 222-223 ), as well as for the treatment of Parkinson's diseases (J. Neurosurg, 1985, 63, pp. 321-341) and Alzheimer's (Brain Research, 1990, 528, pp.
- the compounds of the present invention in addition to their novelty, show a very high affinity for melatonin receptors.
- the present invention relates more particularly to the compounds of formula (I):
- R represents a linear or branched (C 1 -C 6 ) alkyl group, a (C 3 -C 8 ) cycloalkyl group or a linear or branched (C 3 -C 8 ) (C 1 -C 6 ) alkyl (C 3 -C 8 ) alkyl group;
- R advantageously represents a linear or branched (C 1 -C 6 ) alkyl group and, more particularly, the methyl, ethyl and propyl groups.
- the invention relates to the compounds which are: N- [3-hydroxy-2- (5-methoxy-1H-indol-3-yl) propyl] acetamide,
- the invention also extends to the process for the preparation of the compound of formula (I), characterized in that the compound of formula (II) used is the starting material:
- the pharmacological study of the derivatives of the invention has shown that they are atoxic, endowed with a high selective affinity for melatonin receptors and have important activities on the central nervous system and, in particular, have been noted.
- therapeutic properties on sleep disorders, antidepressant, anxiolytic, antipsychotic, analgesic and microcirculation properties which make it possible to establish that the products of the invention are useful in the treatment of stress, sleep disorders, anxiety, seasonal depression or major depression, cardiovascular pathologies, pathologies of the digestive system, insomnia and fatigue due to jet lag, schizophrenia, panic attacks, melancholy, disorders of the appetite, obesity, insomnia, psychotic disorders, epilepsy, diabetes, Parkinson's disease, senile dementia, various disorders related to normal or pathological aging, migraine, memory loss, Alzheimer's disease, as well as disorders of the cerebral circulation.
- the products of the invention can be used in malfunctions they possess the properties of ovulation inhibitors, immunomodulators and that they are likely to
- the compounds will preferably be used in the treatment of major depression, seasonal depression, sleep disorders, cardiovascular pathologies, pathologies of the digestive system, insomnia and fatigue due to jet lag, appetite disorders and obesity.
- the compounds will be used in the treatment of major depression, seasonal depression and sleep disorders.
- the present invention also relates to pharmaceutical compositions containing at least one compound of formula (I) alone or in combination with one or more pharmaceutically acceptable excipients.
- compositions according to the invention mention may be made, more particularly, of those which are suitable for oral, parenteral, nasal, percutaneous, rectal, perlingual, ocular or respiratory administration and in particular simple or coated tablets, sublingual tablets. , sachets, packets, capsules, glossettes, lozenges, suppositories, creams, ointments, dermal gels, and oral or injectable ampoules.
- compositions cited above illustrate the invention but do not limit it in any way.
- the dosage varies according to the sex, age and weight of the patient, the route of administration, the nature of the therapeutic indication, or possibly associated treatments and ranges between 0.01 mg and 1 g per 24 hours. in one or more takes.
- the following examples illustrate the invention and do not limit it in any way.
- the starting materials used are known products or prepared according to known procedures.
- the structures of the compounds, described in the examples, were determined according to the usual spectroscopic techniques (infrared, NMR, mass spectrometry, etc.).
- Step B Under argon, 800 mg (2.6 mmol) of the compound obtained in Step B are dissolved in 10 ml of freshly distilled tetrahydrofuran. To this mixture at 0 ° C. are added portionwise 200 mg (5.2 mmol) of aluminum hydride and lithium. At the end of the addition, the ice bath is removed. After stirring for 20 minutes, the mixture is cooled to 0 ° C. and then trapped with water. The medium is extracted with dichloromethane, washed twice with saturated sodium chloride solution and once with water.
- the S enantiomer was obtained by separation on a chiral preparative column.
- Acute toxicity was assessed after oral administration to batches of 8 mice (26 ⁇ 2 grams). The animals were observed at regular intervals during the first day and daily for two weeks after treatment. The LD 50, resulting in the death of 50% of the animals, was evaluated and showed the low toxicity of the compounds of the invention.
- the compounds of the invention are tested in a behavioral model, the forced swimming test.
- the apparatus consists of a Plexiglas cylinder filled with water.
- the animals are tested individually during a 6-minute session. At the beginning of each test, the animal is placed in the center of the cylinder. The downtime is recorded. Each animal is judged immobile when it ceases to struggle, and remains on the surface of the water, motionless, making only the movements allowing it to keep its head out of the water.
- the compounds of the invention significantly reduce the duration of immobilization attesting to their antidepressant activity.
- MTi or MT 2 receptor binding experiments were performed using 2- [ 125 I] -iodomelatonin as a reference radioligand. The retained radioactivity is determined using a liquid scintillation counter.
- the Kj values found for the compounds of the invention attest to a binding for one or other of the melatoninergic binding sites, these values being ⁇ 10 ⁇ M.
- the compound obtained in Example 1 has a Kj (MT 1 ) of 49.1 nM, and a K 1 (MT 2 ) of 5.7 nM.
- the rats receive a daily administration of the test molecule.
- the compounds of the invention are tested in a behavioral model, the light / dark cages test, which reveals the anxiolytic activity of the molecules.
- the device consists of two polyvinyl boxes covered with Plexiglas. One of these boxes is obscure. One lamp is placed above the other box giving a luminous intensity in the center of it of approximately 4000 lux. An opaque plastic tunnel separates the clear box from the dark box. The animals are individually tested during a 5-minute session. The floor of each box is cleaned between each session. At the beginning of each test, the mouse is placed in the tunnel, facing the dark box. The time spent by the mouse in the lighted box and the number of transitions through the tunnel are recorded after the first entry in the dark box. After administration of the compounds 30 minutes before the start of the test, the compounds of the invention significantly increase the time spent in the lit cage and the number of transitions, which shows the anxiolytic activity of the derivatives of the invention.
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2744178A CA2744178A1 (fr) | 2008-11-25 | 2009-11-24 | Derives indoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
CN2009801473230A CN102224138A (zh) | 2008-11-25 | 2009-11-24 | 吲哚衍生物、其制备方法以及包含这些吲哚衍生物的药物组合物 |
BRPI0920898A BRPI0920898A2 (pt) | 2008-11-25 | 2009-11-24 | derivados de indóis, processo de preparação e composições farmacêuticas que os contêm. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0806599A FR2938839A1 (fr) | 2008-11-25 | 2008-11-25 | Nouveaux derives indoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
FR08.06599 | 2008-11-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010061074A1 true WO2010061074A1 (fr) | 2010-06-03 |
Family
ID=40902727
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2009/001338 WO2010061074A1 (fr) | 2008-11-25 | 2009-11-24 | Derives indoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Country Status (6)
Country | Link |
---|---|
CN (1) | CN102224138A (fr) |
AR (1) | AR074395A1 (fr) |
BR (1) | BRPI0920898A2 (fr) |
CA (1) | CA2744178A1 (fr) |
FR (1) | FR2938839A1 (fr) |
WO (1) | WO2010061074A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105085366A (zh) * | 2014-05-07 | 2015-11-25 | 北京生命科学研究所 | 一种吲哚骨架化合物及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0078431A1 (fr) * | 1981-10-28 | 1983-05-11 | Miles Laboratories, Inc. | Méthyl-3-acétamido-2-(5-méthoxy-indol-3-yl)propanoate |
-
2008
- 2008-11-25 FR FR0806599A patent/FR2938839A1/fr not_active Withdrawn
-
2009
- 2009-11-24 CA CA2744178A patent/CA2744178A1/fr not_active Abandoned
- 2009-11-24 WO PCT/FR2009/001338 patent/WO2010061074A1/fr active Application Filing
- 2009-11-24 AR ARP090104513A patent/AR074395A1/es unknown
- 2009-11-24 BR BRPI0920898A patent/BRPI0920898A2/pt not_active Application Discontinuation
- 2009-11-24 CN CN2009801473230A patent/CN102224138A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0078431A1 (fr) * | 1981-10-28 | 1983-05-11 | Miles Laboratories, Inc. | Méthyl-3-acétamido-2-(5-méthoxy-indol-3-yl)propanoate |
Non-Patent Citations (11)
Title |
---|
"Melatonin - Clinical Perspectives", 1988, OXFORD UNIVERSITY PRESS, pages: 164 - 165 |
BRAIN RESEARCH, vol. 528, 1990, pages 170 - 174 |
CLINICAL ENDOCRINOLOGY, vol. 24, 1986, pages 359 - 364 |
INTERNATIONAL JOURNAL OF EATING DISORDERS, vol. 20, no. 4, 1996, pages 443 - 446 |
J. NEUROSURG., vol. 63, 1985, pages 321 - 341 |
NEUROPHARMACOLOGY OF PINEAL SECRETIONS, vol. 8, no. 3-4, 1990, pages 264 - 272 |
PARKINSON, J. NEUROSURG., vol. 63, 1985, pages 321 - 341 |
PHARMACOPSYCHIAT., vol. 20, 1987, pages 222 - 223 |
PSYCHOPHARMACOLOGY, vol. 100, 1990, pages 222 - 226 |
SAFDY M E ET AL: "TRYPTOPHAN ANALOGUES. 1. SYNTHESIS AND ANTIHYPERTENSIVE ACTIVITY OF POSITIONAL ISOMERS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 25, no. 6, 1 January 1982 (1982-01-01), pages 723 - 730, XP001108982, ISSN: 0022-2623 * |
SCIENCE, vol. 227, 1987, pages 714 - 720 |
Also Published As
Publication number | Publication date |
---|---|
FR2938839A1 (fr) | 2010-05-28 |
BRPI0920898A2 (pt) | 2015-12-29 |
AR074395A1 (es) | 2011-01-12 |
CN102224138A (zh) | 2011-10-19 |
CA2744178A1 (fr) | 2010-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1077927B1 (fr) | Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
WO2008000969A1 (fr) | Nouveaux derives naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EP0745583A1 (fr) | Composés alkoxy-aryles ayant une affinité pour les récepteurs mélatoninergiques, leur procédé de préparation, et les compositions pharmaceutiques qui les contiennent | |
EP2079689A2 (fr) | Derives indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EP1873140B1 (fr) | Nouveaux dérivés naphtaleniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
EP1466604B1 (fr) | Nouveaux dérivés d'isoquinoléine, leur procédé de préparation et leur utilisation pour traiter les troubles du système mélatoninergique | |
WO2006027474A2 (fr) | Nouveaux derives d ' imidazopyridine presentant une affinite vis a vis des recepteurs de la melatonine , leur procede de preparation et les compositions pharmaceutiques qui les contiennet | |
CA2666497A1 (fr) | Nouveaux derives indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
WO2009022064A2 (fr) | Nouveaux derives naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
CA2593618C (fr) | Derives naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
WO2010061074A1 (fr) | Derives indoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
WO2009022066A2 (fr) | Nouveaux derives naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
WO2009022062A1 (fr) | Nouveaux derives naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
WO2005012282A1 (fr) | Nouveaux derives du benzothiofene 2-thiosubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EP2167460A2 (fr) | Nouveaux derives naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EP1317413A1 (fr) | Derives biphenyles substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
WO2005012229A1 (fr) | Nouveaux derives bicycliques alkyles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
WO2009022065A2 (fr) | Nouveaux derives naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EP1558566A1 (fr) | Nouveaux derives du phenylnaphtalene, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980147323.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09768113 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2744178 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011538019 Country of ref document: JP Ref document number: MX/A/2011/005496 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09768113 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: PI0920898 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110524 |